This also suggests whether we can consider MetS as a risk factor for promoting early metastasis of prostate cancer.Although patients with MetS may have elevated initial serum testosterone levels and high PSA, they also present a number of problems for follow-up treatment such as a shortened treatment window and treatment insensitivity. The gene discussed is KLK3; the disease is prostate carcinoma.